Cardiovascular Danger Reduction Study Reduction In Recurrent Important Cv Illness Events Complete Text View
Given the OS benefit now we’ve noticed across all 3 of the Phase 3 trials in the metastatic setting we’ve carried out to date, on the left-hand side, you can see the benefits that we’ve generated in the very first-line metastatic setting. You can see impressive threat...